stockrow
Friday 6 November 2026
Export CRSP’s income statement to Excel — free account
CRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
- Revenue
- +1,325.1%
- EPS
- +1.55%
- Free cash flow
- −6.36%
Quarter to September 2026, against a year earlier
49.92
1.36
+2.80%
Follow CRSP
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 3 | 4 | 2 | 7 | 3 | 6 | 2 | 3 | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 15.19 | 0.00 | 54.87 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
7.04 | 5.89 | 8.76 | 4.57 | 11.48 | 36.99 | 16.78 | 7.67 | 6.51 | 1.50 |
P/S ratio |
1,343.49 | 88.98 | 14.10 | 2,660.79 | 6.29 | 14,043.96 | 11.44 | 438.65 | 24.59 | 53.41 |
Altman Z″-Score (non-manufacturers) |
6.42 | 8.57 | 8.86 | 7.18 | 13.31 | 14.17 | 13.08 | 6.01 | 4.91 | 5.98 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 12.59 | 0.00 | 66.27 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(50.95) | (66.37) | (54.47) | (28.13) | (66.89) | (124.34) | 981.34 | (48.30) | (67.93) | (14.20) |
Beneish M-Score |
— | (4.94) | 272.49 | 25,201.83 | 1,131.22 | 438.23 | 80.41 | (7.56) | 3.19 | 15.89 |
P/B ratio |
2.45 | 1.72 | 2.78 | 1.70 | 2.40 | 6.07 | 3.53 | 3.49 | 5.37 | 1.18 |
Price to Tangible BV |
2.45 | 1.72 | 2.78 | 1.70 | 2.40 | 6.07 | 3.53 | 3.50 | 5.38 | 1.19 |
EV/Sales |
845.25 | 44.05 | 10.15 | 1,335.82 | 3.92 | 11,762.55 | 8.33 | 292.47 | 18.74 | (7.69) |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 9.17 | 0.00 | 46.89 | 0.00 | 0.00 | 0.59 |
EV/Operating CF |
(8.60) | (11.51) | (14.47) | (3.23) | 6.66 | (35.48) | 42.58 | (9.49) | (10.96) | 0.72 |
EV/FCF |
(8.58) | (11.36) | (13.96) | (3.00) | 7.85 | (32.94) | 48.27 | (9.23) | (9.86) | 0.68 |
Quick Ratio |
13.25 | 21.97 | 17.41 | 15.08 | 19.85 | 17.93 | 16.53 | 16.46 | 16.70 | 14.49 |
Current Ratio |
13.32 | 22.07 | 17.54 | 15.30 | 20.17 | 18.21 | 17.29 | 16.81 | 17.12 | 14.56 |
Net Debt/EBITDA |
3.06 | 4.26 | 8.36 | 2.80 | (6.08) | 4.92 | (18.34) | 2.94 | 3.89 | 4.69 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.02 | 0.17 | 0.00 | 0.40 | 0.00 | 0.37 | 0.01 | 0.13 | 0.02 |
Operating CF/Net income |
0.59 | 0.39 | 1.70 | 0.76 | 1.43 | 0.68 | 0.85 | 0.58 | 1.03 | 2.39 |
Capex/Depreciation |
(0.05) | (0.10) | (0.48) | (1.54) | (4.55) | (1.66) | (1.41) | (0.79) | (2.58) | (3.26) |
Interest Coverage |
— | — | — | — | — | — | — | — | — | (8.46) |
| (30.18%) | (19.20%) | (8.17%) | (30.42%) | 18.59% | (26.80%) | 10.04% | (56.89%) | (32.50%) | (22.75%) | |
| (25.81%) | (16.38%) | (6.87%) | (26.03%) | 16.49% | (24.10%) | 8.59% | (43.40%) | (22.18%) | (9.19%) | |
ROIC |
0.00% | (1,032.08%) | (73.55%) | (699.33%) | 1,148.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(29.79%) | (18.47%) | (7.87%) | (34.30%) | 15.51% | (20.96%) | 6.95% | (36.09%) | (27.05%) | (7.26%) |
Average Days of Receivables |
0.00 | 244.55 | 196.66 | 3,351.42 | 0.12 | 73.10 | 0.12 | 10.28 | 23.38 | 223.14 |
Research and Development Expense of Revenue |
10,856.38% | 831.42% | 104.34% | 38,534.64% | 37.22% | 37,127.40% | 61.94% | 3,641.90% | 170.26% | 817.93% |
Selling, General and Administrative Expense of Revenue |
2,095.21% | 195.58% | 20.52% | 8,552.92% | 10.90% | 12,268.15% | 21.92% | 1,545.90% | 87.43% | 601.39% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
2,065.50% | 232.00% | 21.83% | 8,175.88% | 11.19% | 9,181.92% | 15.21% | 1,119.88% | 46.04% | 209.99% |
Graham Net Nets |
0.35 | 0.49 | 0.30 | 0.47 | 0.36 | 0.15 | 0.26 | 0.27 | 0.16 | 0.75 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 59.56 | 0.00 | 20.77 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(12.43%) | (11.10%) | (2.94%) | (20.41%) | 6.58% | (3.44%) | 1.82% | (12.01%) | (6.83%) | (22.30%) |
Free Cash Flow Yield |
(7.34%) | (4.36%) | (5.16%) | (16.72%) | 7.94% | (2.54%) | 1.51% | (7.23%) | (7.73%) | (21.15%) |
Revenue per Share |
0.04 | 0.44 | 4.69 | 0.02 | 12.05 | 0.01 | 5.32 | 0.07 | 1.02 | 0.42 |
Operating CF per Share |
(3.84) | (1.69) | (3.29) | (6.38) | 7.10 | (3.61) | 1.04 | (2.01) | (1.75) | (4.51) |
Capex per Share |
(0.01) | (0.02) | (0.12) | (0.48) | (1.08) | (0.28) | (0.12) | (0.06) | (0.20) | (0.25) |
Free Cash Flow per Share |
(3.85) | (1.71) | (3.41) | (6.85) | 6.02 | (3.89) | 0.92 | (2.06) | (1.94) | (4.76) |
Cash per Share |
21.97 | 22.57 | 21.38 | 23.35 | 31.33 | 25.63 | 17.35 | 9.52 | 5.99 | 25.74 |
Shareholders Equity per Share |
21.37 | 22.90 | 23.77 | 24.12 | 31.59 | 25.23 | 17.27 | 8.18 | 4.69 | 19.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
21.37 | 22.90 | 23.77 | 24.12 | 31.59 | 25.23 | 17.27 | 8.18 | 4.69 | 19.00 |
Free Cash Flow |
(345.93) | (144.67) | (269.84) | (532.93) | 457.27 | (256.72) | 49.99 | (99.01) | (77.91) | (58.33) |
Working Capital |
1,836.55 | 1,849.35 | 1,799.29 | 1,731.92 | 2,297.63 | 1,622.36 | 930.44 | 438.65 | 233.87 | 298.19 |
Capital Expenditures |
(0.91) | (1.90) | (9.47) | (37.19) | (81.70) | (18.36) | (6.68) | (2.77) | (7.81) | (3.02) |
Net Current Asset Value |
1,642.24 | 1,627.18 | 1,561.31 | 1,485.45 | 2,065.10 | 1,552.89 | 860.22 | 369.57 | 164.87 | 208.07 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 9.61 | 0.00 | 51.63 | 0.00 | 0.00 | 0.58 |
Capex to Sales |
0.26 | 0.05 | 0.03 | 31.04 | 0.09 | 25.53 | 0.02 | 0.89 | 0.19 | 0.58 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 15.41 | 0.00 | 70.88 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.17 | 0.14 | 0.13 | 0.15 | 0.13 | 0.26 | 0.15 | 0.19 | 0.16 | 0.04 |
Cash ROIC |
(8.88%) | (3.77%) | (7.54%) | (14.44%) | 9.57% | (7.65%) | 2.65% | (11.66%) | (18.22%) | (10.64%) |
Accounts Receivable Turnover |
0.00 | 0.33 | 3.52 | 0.21 | 4,075.56 | 5.92 | 3,097.22 | 2.30 | 14.18 | 2.95 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Receivables |
— | 112.50 | 105.50 | 5.65 | 0.22 | 0.12 | 0.09 | 1.36 | 2.89 | 1.75 |
Average Payables |
12.92 | 26.43 | 32.79 | 21.12 | 11.96 | 7.52 | 5.51 | 3.35 | 3.10 | 3.08 |
Average Assets |
2,253.64 | 2,235.80 | 2,236.31 | 2,497.47 | 2,289.92 | 1,447.36 | 777.88 | 380.18 | 308.15 | 252.19 |
Average Common Equity |
1,926.95 | 1,907.44 | 1,879.14 | 2,137.47 | 2,031.85 | 1,301.83 | 665.81 | 290.01 | 210.34 | 101.86 |
Columns are period end dates · fundamentals updated 6 Nov 2026